NCT05897242

A Smartphone Application (ACT on Vaping) for Vaping Cessation in Young Adults

Completed NA Results posted Last updated 24 June 2025

What this trial tests

NA trial testing Smartphone app in Nicotine Dependence in 61 participants. Completed in 26 April 2024.

Timeline

4 January 2024

Primary endpoint
26 April 2024

26 April 2024

Quick facts

Lead sponsor	Fred Hutchinson Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	61
Start date	4 January 2024
Primary completion	26 April 2024
Estimated completion	26 April 2024
Sites	1 location across United States

Drugs / interventions tested

• Smartphone app
• Text Message — full drug profile →
• Survey Administration

Conditions studied

• Nicotine Dependence — all drugs for Nicotine Dependence →
• Nicotine Addiction — all drugs for Nicotine Addiction →
• Nicotine Use Disorder — all drugs for Nicotine Use Disorder →
• Nicotine Vaping — all drugs for Nicotine Vaping →

Sponsor

Fred Hutchinson Cancer Center — full company profile →

Who can join

Adults 18 to 30, any sex, with Nicotine Dependence or Nicotine Addiction. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Overall Treatment Satisfaction Rating Primary · At 3 months post-randomization

We calculated descriptive statistics (mean, standard deviation) for the primary acceptability benchmark of overall satisfaction averaging at least 3.5 on a 1-5 Likert-type scale within the ACT on Vaping arm only. Overall satisfaction was assessed with a 5-point Likert-type item on the 3-month follow-up survey, with response options ranging from (1) "not at all" to (5) "very much." The ACT on Vaping benchmark average of 3.5 falls between ratings of 3="somewhat" and 4="mostly." Higher values are associated with a higher level of satisfaction.

Group	Value	95% CI
Arm I (Act on Vaping App)	3.8	± 1.3

Change in Readiness to Quit Primary · From baseline to 3 months post-randomization

Will evaluate differences of Contemplation Ladder scores. The 1-item Contemplation Ladder, scores range from 0-10, was used to assess readiness to quit using e-cigarettes. The higher the score, the more ready the person is to make a change. The anchor for the cut-off score of 5, indicating high vs. low quit readiness, is "Think I should quit but not quite ready."

Group	Value	95% CI
Arm I (Act on Vaping App)	0.96	± 2.0
Arm II (Incentivized Text Message Check-ins)	0.72	± 1.7

Percentage of Participants With a 24-hour Quit Attempt Primary · At 3 months post-randomization

Making a 24-hour quit attempt between baseline and 3-month follow-up was assessed via self-report at the 3-month follow-up survey. The percentage of participants with self-reported 24-hour quit attempts is evaluated descriptively.

Group	Value	95% CI
Arm I (Act on Vaping App)	21
Arm II (Incentivized Text Message Check-ins)	22

Cotinine-confirmed 30-day Point Prevalence Abstinence From All Nicotine and Tobacco Primary · At 3 months post-randomization

Complete case, self-reported 30-day abstinence from all nicotine and tobacco products at 3 months, confirmed via saliva cotinine testing. Differences were evaluated descriptively.

Group	Value	95% CI
Arm I (Act on Vaping App)	1
Arm II (Incentivized Text Message Check-ins)	0

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected by a web-based survey (on Day 21, 42, 63, and at the 3-month follow-up time point).. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Arm I (Act on Vaping App)

Serious: 0/31 (0%)

Deaths: 0/31

Arm II (Incentivized Text Message Check-ins)

Serious: 0/30 (0%)

Deaths: 0/30

Other adverse events (4 terms — click to expand)

Reaction	System	Arm I (Act on Vaping App)	Arm II (Incentivized Text …
COVID-19 infection	Respiratory, thoracic and mediastinal disorders	—	—
Worsening of pre-existing mental health condition	Psychiatric disorders	—	—
Lowered resting heart rate	Cardiac disorders	—	—
Burn on inner thigh.	Skin and subcutaneous tissue disorders	—	—

Data from ClinicalTrials.gov NCT05897242 adverse events section.

Sponsor's own description

Almost one in ten young adults report current e-cigarette use, putting them at risk of developing nicotine addiction and long-term health effects of exposure to inhaled toxicants. Despite the need for effective treatments to help these young users quit, very few treatments targeting any type of tobacco use among young adults have been evaluated, particularly for young adults who vape and have unique treatment needs. To address these needs, this trial will evaluate a digital program for young adult e-cigarette users at all stages of readiness to quit called ACT on Vaping.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. ACT on Vaping: Pilot Randomized Controlled Trial of a Novel Digital Health App With Text Messaging for Young Adult Vaping Cessation.
   Heffner JL, Baker K, Georgiou K, Graham AL, et al · · 2026 · cited 2× · PMID 40411791 · DOI 10.1093/ntr/ntaf112